Extended Data Fig. 1: mAb neutralization against SIV isolates, and fully and partially neutralizing LS mAb pharmacokinetics in plasma.
From: Antibody prophylaxis may mask subclinical SIV infections in macaques
(A) Neutralization activity of study mAbs against SIVsmE660.A8.CP3C (tier 1), SIVsmE660.2A5.CR54 (tier 2), and SIVmac239 (tier 3). Longitudinal plasma (B) ITS06.02, (C) ITS103.01, (D) ITS01 and ITS06.02, and (E) ITS103.01 and ITS06.02 mAb concentrations in animals from groups 2–5, respectively, from fully and partially neutralizing antibody infusion study relative to days following the first virus challenge. The dose of mAb used is indicated. (D–E) Separate graphs are shown for each mAb.
